CMC Biologics expands GMP manufacturing capacity in Europe

Addition of a Bioreactor 3PACK production facility to its Copenhagen facility provides additional flexible solutions for clients.

"With this additional cGMP production capacity, we are continuing our long-term strategy to provide innovative solutions to our customers, from early-stage development to large-scale commercial production," said Patricio Massera, General Manager of the Copenhagen Site.

With the combination of multiple 2000 L single use bioreactors, CMC Biologics has broken the paradigm that single-use technologies are not applicable for large-scale manufacturing of biologics. Three additional 2000 L single-use production bioreactors will be added in 2017 to complete the fit out of a Bioreactor 6PACK line, thereby establishing identical Bioreactor 6PACK facilities in its US and European manufacturing facilities.

"Establishing this unique facility design in both our US and European manufacturing facilities enables us to significantly optimize process transfer and synergies between the sites. This provides our customers with the production scale and flexibility needed in today's market, and enables our client to meet aggressive regulatory and production timelines," said Gustavo Mahler, President and CEO of CMC Biologics and added, "We are changing the way CMOs operate and we continue to generate innovative solutions for our clients."